V1. Studies of the epidemiology of viral infections
Oral Abstract Submission
Angela Branche, MD
Assistant Professor of Medicine
University of Rochester
Rochester, NY
Disclosure: GSK: Consultant
Mercke Dohme and Sharpe: Consultant, Grant/Research Support
Pfizer: Grant/Research Support
Lisa Saiman, MD, MPH
Professor of Pediatrics
Columbia University Irving Medical Center
New York, NY
Disclosure: Nothing to disclose
Edward E. Walsh, MD
Professor of Medicine
University of Rochester
Rochester, New York
Disclosure: Janssen Pharm: Consultant, no financial payment however
Pfizer: Research Grant
Ann R. Falsey, MD
Dr
University of Rochester
Rochester, NY
Disclosure: Gilead: Consultant, Grant/Research Support
Janssen Pharmaceutical: Consultant
Merck Sharpe and Dome: Consultant, Grant/Research Support
Moderna: Consultant
Pfizer: Consultant, Grant/Research Support
sanofi pasteur: Consultant
William Sieling, MPH
Research Assistant
Columbia University Irving Medical Center
New York, NY
Disclosure: Merck Co., Inc.: Grant/Research Support
Matthew Oberhardt, PhD
Program Director for Research Science
NewYork-Presbyterian Hospital
New York, NY
Disclosure: Merck Co., Inc.: Grant/Research Support
Philip Zachariah, MD, MSc
Assistant Professor of Pediatrics/ Hospital Epidemiologist
Columbia University Irving Medical Center/ NewYork Presbyterian Hospital
New York, NY
Disclosure: Nothing to disclose
William G. Greendyke, MD
Assistant Professor of Medicine
Columbia University Irving Medical Center
New York, NY
Disclosure: Nothing to disclose
Angela Barrett, BA
Research Coordinator
Columbia University Irving Medical Center
New York, NY
Disclosure: Merck Co., Inc.: Grant/Research Support
Celibell Vargas, MD
Research Coordinator
Columbia University Irving Medical Center
New York, NY
Disclosure: Merck Co., Inc.: Grant/Research Support
Luis Alba, B.S.
Research Assistant
Columbia University Irving Medical Center
New York, NY
Disclosure: Nothing to disclose
Matthew R. Phillips, MPH
Study Manager
Merck & Co., Inc.
North Wales, PA
Disclosure: Merck Co., Inc.: Employee
Lyn Finelli, DrPH, MS
Director, Vaccines
Merck & Co., Inc.
Kenilworth, NJ
Disclosure: Merck&Co.: Employee
Background : Background: Respiratory syncytial virus (RSV) infection has been increasingly recognized as an important cause of acute respiratory illness (ARI) and a trigger for exacerbation of underlying cardiopulmonary disease in adults. Incidence of hospitalized RSV infection remains uncertain as adults have not been systematically screened. Previous incidence estimates, derived primarily from modeling studies, have ranged from 84-190/100K population in adults > 65 years of age. Accurate burden data are critical to inform RSV vaccine development for adults. We used active surveillance among hospitalized adults to determine population-based incidence rates of RSV infection.
Methods : Methods: Hospitalized adults ≥ 18 years old residing in the surveillance area with > 2 ARI symptoms or exacerbation of underlying cardiopulmonary disease were screened for eligibility during 10/2017-4/2018 and 10/2018-4/2019 in 3 hospitals in Rochester, NY and New York City. Respiratory specimens were tested for RSV using PCR assays. RSV incidence per 100,000 persons (per 2010 US Census data) was adjusted by percent market share for study hospitals in their catchment area.
Results : Results: 8,217 hospitalized adults residing in the surveillance area that met the surveillance case definition were tested for RSV; 768 (9.4%) were positive. Adults were aged 18-49 (12%), 50-64 (30%), and ≥ 65 years old (58%); 55% were female. RSV infection incidence varied from year 1 to year 2 and was highest in patients aged ≥ 65 years old. (Table)
Conclusion : Conclusion: This is the largest prospective RSV incidence study to date. Preliminary results indicate that the incidence of RSV infection may be higher than previously reported, especially in urban-dwelling adults > 65 years of age. Results confirm the need for vaccines to prevent RSV infections in older adults.
